Skip to main content
. 2014 Oct 27;12(6):719–728. doi: 10.1038/cmi.2014.100

Figure 2.

Figure 2

GM-CSF but not TLR agonists upregulated MR expression. (a) hMR-Tg mice were injected i.p. with 1 ml of 3% thioglycolate on day 1 as well as minus or plus 2 µg of GM-CSF on days 2–4. PEC and BM were collected on day 5 and stained for flow cytometry with 19.2-PE (anti-hMR) or 5D3-PE (anti-mMR). The data shown are the mean±s.d. percentages of MR+ cells in the APC-enriched BM and PEC of four mice per treatment pooled from two independent experiments. Student's t-test compared mice receiving thioglycolate plus or minus GM-CSF (**P<0.01). (b) hMR-Tg mice were injected i.p. with 1 ml of 3% thioglycolate on day 1. These mice subsequently received 2 µg of GM-CSF daily on days 2–4; 25 µg of CpG on day 4; 20 µg of poly-ICLC on day 4; or saline on day 4. PEC were collected on day 5 and stained for flow cytometry with19.2-PE and F4/80-APC-eFluor780, with or without permeabilization to distinguish intracellular or surface hMR. The data shown are the mean±s.d. of hMR+ cells percentages (left) and MFI (right) in the PEC-MΦ of three mice per treatment. Student's t-test: *P<0.05, **P<0.01, compared to thioglycolate plus saline injection. BM, bone marrow; hMR-Tg, human mannose receptor transgenic; i.p., intraperitoneally; MFI, mean fluorescence intensity; PEC, peritoneal exudate cell; TLR, Toll-like receptor.